StorchMKPiddlesdenSHaltiaMIivanainenMMorganPLassmannH. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol1998; 43: 465–71.
2.
WeinshenkerBGO’BrienPCPettersonTM. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol1999; 46: 878–86.
3.
SchirmerLSrivastavaRHemmerB. To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis. Mult Scler2014; 20: 271–9.
4.
SrivastavaRAslamMKalluriSR. Potassium channel KIR4.1 as an immune target in multiple sclerosis. The New England journal of medicine2012; 367: 115–23.
5.
KrausVSrivastavaRKalluriSR. Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease. Neurology2014; 82: 470–3.
6.
HibinoHFujitaAIwaiKYamadaMKurachiY. Differential assembly of inwardly rectifying K+ channel subunits, Kir4.1 and Kir5.1, in brain astrocytes. J Biol Chem2004; 279: 44065–73.
7.
SrivastavaBKalluriSRSchäferY. Differential glycosylation of KIR4.1 in glia cells affects binding of autoantibodies in multiple sclerosis. Mult Scler2014; 20: 341.
8.
SaitoTTaylorGLaverWGKawaokaYWebsterRG. Antigenicity of the N8 influenza A virus neuraminidase: existence of an epitope at the subunit interface of the neuraminidase. J Virol1994; 68: 1790–6.
9.
NerrantESalsacCCharifM. Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis. Mult Scler2014.
10.
BrickshawanaAHinsonSRRomeroMF. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol2014; 13: 795–806.
